Chemoprevention of Pituitary Corticotroph Tumors
垂体促肾上腺皮质激素肿瘤的化学预防
基本信息
- 批准号:7065189
- 负责人:
- 金额:$ 7.62万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-05-11 至 2007-04-30
- 项目状态:已结题
- 来源:
- 关键词:Cushing&aposs syndromeadipocytesadrenocorticotropic hormoneapoptosisblood glucoseblood testschemopreventioncorticosteronecortisolcytokinedietary lipidgenetically modified animalshistopathologyhormone related neoplasm /cancerimidazolelaboratory mouseligandsliver functionnutrition aspect of cancerobesityperoxisome proliferator activated receptorpituitary neoplasmstriterpenesurinalysis
项目摘要
DESCRIPTION (provided by applicant): Cushing's disease, due to an ACTH-secreting pituitary tumor, causes illness due to excess steroid production; no suitable drug therapies are available, and surgical excision, is not always curative. We have demonstrated that ACTH-secreting pituitary tumors express abundant peroxisome proliferators activated receptor-gamma (PPAR-gamma). PPAR-gamma and the retinoid X receptor (RXR) form a permissive heterodimer, that can be activated by either PPAR-gamma and/ or RXR-specific ligands to regulate target gene transcription. Several natural occurring and synthetic PPAR-gamma ligands, including the thiazolidinedione (TZD), rosiglitazone; the non-TZD, GW7845; and the triterpenoid, cyano-3,12- dioxooleaneana-1,9(11)-dien-28-oyl]imidazole (CDDO-IM) bind PPAR-gamma, to regulate multiple actions. PPAR-gamma activation plays a critical role in adipogenesis, glucose metabolism, and placental function, and TZD's are widely used to treat diabetes. Treatment of human and mouse corticotroph pituitary tumor cells in vitro with PPAR-gamma ligands, inhibited tumor growth, and induced corticotroph tumor apoptosis. When athymic Nu/ Nu mice harboring subcutaneous xenografted corticotroph tumors, were treated with rosiglitazone, 4 of 5 treated mice did not develop tumors. Furthermore, plasma ACTH and corticosterone hormone levels were lower in rosiglitazone-treated animals. In addition, rosiglitazone, given to two patients with Cushing's disease, decreased 24 hour urinary cortisol levels by approximately 55% in one patient, and normalized cortisol levels in the second patient. Recently, we have demonstrated potent anti-proliferative, and pro-apoptotic actions of the PPAR-gamma ligand CDDO-IM in corticotroph tumor cells, using 1000-fold lower concentrations than rosiglitazone. This project will examine the chemopreventative actions of CDDO-IM in vivo in the Rb heterozygote knock-out mouse that develops spontaneous pituitary corticotroph tumor. We will also examine the effects of a high fat diet on pituitary corticotroph tumor development, and examine the role of chemopreventative anti-inflammatory treatment with CDDO-IM in the corticotroph tumor model. Our ultimate goal is to develop a rationale for clinical application of these PPAR-gamma ligands as a novel medical therapy in Cushing's disease.
描述(由申请人提供):库欣病是一种分泌acth的垂体肿瘤,由于过量的类固醇产生而导致疾病;没有合适的药物治疗,手术切除并不总是能治愈。我们已经证明垂体acth分泌瘤表达丰富的过氧化物酶体增殖物激活受体- γ (ppar - γ)。ppar - γ和类视黄醇X受体(RXR)形成一个允许的异二聚体,可以被ppar - γ和/或RXR特异性配体激活,以调节靶基因的转录。几种天然存在和合成的ppar - γ配体,包括噻唑烷二酮(TZD),罗格列酮;非tzd, GW7845;而三萜类化合物氰-3,12-二氧齐烷-1,9(11)-二烯-28-酰基]咪唑(CDDO-IM)结合ppar - γ,调节多种作用。ppar - γ激活在脂肪形成、葡萄糖代谢和胎盘功能中起着关键作用,TZD被广泛用于治疗糖尿病。ppar - γ配体体外处理人和小鼠垂体促皮质瘤细胞,抑制肿瘤生长,诱导促皮质瘤细胞凋亡。当含有皮下异种移植皮质性肿瘤的胸腺Nu/ Nu小鼠接受罗格列酮治疗时,5只小鼠中有4只未发生肿瘤。此外,罗格列酮治疗的动物血浆ACTH和皮质酮激素水平较低。此外,两名库欣病患者服用罗格列酮后,其中一名患者24小时尿皮质醇水平降低约55%,另一名患者皮质醇水平正常化。最近,我们已经证明ppar - γ配体CDDO-IM在促皮质性肿瘤细胞中具有有效的抗增殖和促凋亡作用,使用浓度比罗格列酮低1000倍。本项目将研究CDDO-IM在Rb杂合子敲除小鼠体内发生自发性垂体促皮质性肿瘤的化学预防作用。我们还将研究高脂肪饮食对垂体促皮质性肿瘤发展的影响,并研究CDDO-IM化学预防抗炎治疗在促皮质性肿瘤模型中的作用。我们的最终目标是为这些ppar - γ配体作为库欣病的一种新的药物治疗方法的临床应用开发一个基本原理。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Targeting pituitary tumors.
针对垂体肿瘤。
- DOI:10.1159/000110608
- 发表时间:2007
- 期刊:
- 影响因子:0
- 作者:Heaney,AnthonyP
- 通讯作者:Heaney,AnthonyP
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANTHONY P HEANEY其他文献
ANTHONY P HEANEY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANTHONY P HEANEY', 18)}}的其他基金
Development of a patient-derived tumoroid culture system to explore novel medical treatments for refractory prolactinomas
开发患者源性肿瘤培养系统,探索难治性泌乳素瘤的新疗法
- 批准号:
10643450 - 财政年份:2023
- 资助金额:
$ 7.62万 - 项目类别:
Identification of TR4 Modulators for Treatment of Cushing Disease.
用于治疗库欣病的 TR4 调节剂的鉴定。
- 批准号:
10199436 - 财政年份:2021
- 资助金额:
$ 7.62万 - 项目类别:
Development of 3-dimensional human pituitary corticotroph tumor cultures as a preclinical model for drug discovery
开发 3 维人垂体促肾上腺皮质激素肿瘤培养物作为药物发现的临床前模型
- 批准号:
10448514 - 财政年份:2021
- 资助金额:
$ 7.62万 - 项目类别:
Development of 3-dimensional human pituitary corticotroph tumor cultures as a preclinical model for drug discovery
开发 3 维人垂体促肾上腺皮质激素肿瘤培养物作为药物发现的临床前模型
- 批准号:
10653709 - 财政年份:2021
- 资助金额:
$ 7.62万 - 项目类别:
Development of 3-dimensional human pituitary corticotroph tumor cultures as a preclinical model for drug discovery
开发 3 维人垂体促肾上腺皮质激素肿瘤培养物作为药物发现的临床前模型
- 批准号:
10297675 - 财政年份:2021
- 资助金额:
$ 7.62万 - 项目类别:
Refined Fructose Promotes Pancreatic Cancer Growth
精制果糖促进胰腺癌生长
- 批准号:
7904018 - 财政年份:2007
- 资助金额:
$ 7.62万 - 项目类别:
Refined Fructose Promotes Pancreatic Cancer Growth
精制果糖促进胰腺癌生长
- 批准号:
8137007 - 财政年份:2007
- 资助金额:
$ 7.62万 - 项目类别:
Refined Fructose Promotes Pancreatic Cancer Growth
精制果糖促进胰腺癌生长
- 批准号:
7667840 - 财政年份:2007
- 资助金额:
$ 7.62万 - 项目类别:
Refined Fructose Promotes Pancreatic Cancer Growth
精制果糖促进胰腺癌生长
- 批准号:
7502595 - 财政年份:2007
- 资助金额:
$ 7.62万 - 项目类别:
Refined Fructose Promotes Pancreatic Cancer Growth
精制果糖促进胰腺癌生长
- 批准号:
7371529 - 财政年份:2007
- 资助金额:
$ 7.62万 - 项目类别:
相似海外基金
Structural and biochemical investigation of the Bloom�s complex, defective in Bloom�s Syndrome
布卢姆综合征缺陷的布卢姆复合体的结构和生化研究
- 批准号:
nhmrc : 1033592 - 财政年份:2012
- 资助金额:
$ 7.62万 - 项目类别:
NHMRC Project Grants
Immuno-pathophysiology of Lymphocytic Foci in Sjogren?s Syndrome
干燥综合征淋巴细胞病灶的免疫病理生理学
- 批准号:
8518291 - 财政年份:2011
- 资助金额:
$ 7.62万 - 项目类别:
An investigation of the role of brain amyloid in cognition, brain atrophy and Alzheimer s disease in Down s syndrome
脑淀粉样蛋白在唐氏综合症认知、脑萎缩和阿尔茨海默病中作用的研究
- 批准号:
G1002252/1 - 财政年份:2011
- 资助金额:
$ 7.62万 - 项目类别:
Research Grant
Immuno-pathophysiology of Lymphocytic Foci in Sjogren?s Syndrome
干燥综合征淋巴细胞病灶的免疫病理生理学
- 批准号:
8311959 - 财政年份:2011
- 资助金额:
$ 7.62万 - 项目类别:
Immuno-pathophysiology of Lymphocytic Foci in Sjogren?s Syndrome
干燥综合征淋巴细胞病灶的免疫病理生理学
- 批准号:
8321067 - 财政年份:2011
- 资助金额:
$ 7.62万 - 项目类别:
Immunotherapeutic analysis using newly established murine models for Sjogren' s syndrome
使用新建立的干燥综合征小鼠模型进行免疫治疗分析
- 批准号:
21249090 - 财政年份:2009
- 资助金额:
$ 7.62万 - 项目类别:
Grant-in-Aid for Scientific Research (A)
Salivary glands reproduction and reacquisition of saliva secretion ability on the new Sjogren' s syndrome model mice.
新干燥综合征模型小鼠唾液腺的繁殖和唾液分泌能力的重新获得。
- 批准号:
21592530 - 财政年份:2009
- 资助金额:
$ 7.62万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Research of γδ T cells in Sjogren, s syndrome model mouse
干燥综合征模型小鼠γδT细胞的研究
- 批准号:
19599009 - 财政年份:2007
- 资助金额:
$ 7.62万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular analyses of UV^s syndrome and development of simple diagnostic methods for inherited photosensitive diseases
UV综合征的分子分析和遗传性光敏性疾病简单诊断方法的开发
- 批准号:
09670887 - 财政年份:1997
- 资助金额:
$ 7.62万 - 项目类别:
Grant-in-Aid for Scientific Research (C)